This study was carried out at Maharaj Nakorn Chiang Mai hospital, a tertiary center and medical school. It is a diagnostic research performed as a second analysis using our prospective database, constructed under the project “Down syndrome screening” of National Research University of Thailand. Regarding the database development, pregnant women attending our antenatal care unit in the first trimester and those who were referred from other hospitals in the northern region of Thailand for fetal aneuploidy screening were screened with maternal serum biomarkers or nuchal translucency (NT) in the first trimester. All women participating in the project were systematically approached, and the following data were prospectively recorded: demographic data (maternal age, body weight, ethnicity, smoking habit, underlying medical disease, etc.), obstetric data (menstrual history, previous pregnancy complications, etc.), Down syndrome screening results, serum biomarker profiles and first trimester ultrasound parameters including crown-rump length (CRL), nuchal translucency (NT), nasal bone (NB), tricuspid regurgitation (TR), ductus venosus (DV) waveforms, and obstetric outcomes. A sonomarker was considered abnormal (positive test) under the following conditions: 1) NT was greater than 95th percentile of the Thai reference range(19); 2) the absence of nasal bone; 3) the presence of tricuspid regurgitation (at least half of systole with a velocity over 60 cm./sec(20); or 4) reversed a-wave of the DV Doppler waveforms. All pregnant women were counseled and offered the first trimester combined test, and they provided written informed consent. Further, all women were followed up for pregnancy outcomes, which were assessed by the obstetricians, while neonatal outcomes were assessed by the pediatricians of the research team.
The study population was pregnant women attending our antenatal care clinic from January 2010 to November 2019, who met the following inclusion criteria: 1) singleton pregnancy, 2) gestational age of 11 to 13 +6 weeks, based on crown-rump length in the first trimester, measured on the day of recruitment, and 3) known final fetal diagnosis of Down syndrome status. The diagnosis of Down syndrome was based on chromosome studies: karyotypes derived from chorionic villus sampling, amniocentesis, cordocentesis or neonatal work-up. The diagnosis of “no” Down syndrome was made by chromosome studies or concluded by the neonatologists based on clinical findings in cases for which chromosome study was not done. Exclusion criteria were cases with fetal structural anomalies other than trisomy 21 and unavailability of final outcomes.
Ultrasound assessments of NT thickness, the presence of NB, TR and abnormal DV waveforms were performed by the maternal-fetal medicine (MFM) staff members and MFM fellows, using either Aloka machines : Prosound α-10, α-7, or α-6 (Aloka Co, Ltd, Tokyo, Japan) or Voluson E8 (GE Medical Systems, Zipf, Austria), equipped with transducers of 3.5-MHz-frequency. The measurement of NT, NB, TR and DV followed the standard techniques suggested by previous studies (7, 14, 20, 21).
Regarding analysis, the database was accessed to retrieve all the consecutive records meeting the inclusion criteria mentioned above. This study obtained ethical approval from the Institutional Review Boards, Faculty of Medicine, Chiang Mai University (Study code: OBG-2562-06961).
Statistical analysis: The analysis was performed using SPSS version 21.0 (IBM Corp. Released 2012; IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp). The sensitivity (detection rate) and false positive rate with 95% CI of each parameter and their combinations in predicting fetal Down syndrome were calculated.